Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Zanmei Xu
PD-L1 Is a Direct Target of Cancer-Foxp3 in Pancreatic Ductal Adenocarcinoma (PDAC), and Combined Immunotherapy With Antibodies Against PD-L1 and CCL5 Is Effective in the Treatment of PDAC
Signal Transduction and Targeted Therapy
Cancer Research
Genetics
Related publications
Prognostic Value, Localization and Correlation of PD-1/PD-L1, CD8 and FOXP3 With the Desmoplastic Stroma in Pancreatic Ductal Adenocarcinoma
Oncotarget
Oncology
Overexpression of Mesothelin in Pancreatic Ductal Adenocarcinoma (PDAC)
International Journal of Medical Sciences
Medicine
PD-1/PD-L1 Blockade: A New Promising Therapy for the Treatment of Pancreatic Cancer?
Pancreas - Open Journal
PD-1/PD-L1: A Novel Target for Immunotherapy in Patients With Advanced and Metastatic Non-Small Cell Lung Cancer
Medicinski podmladak
MSP-RON Signaling Is Activated in the Transition From Pancreatic Intraepithelial Neoplasia (PanIN) to Pancreatic Ductal Adenocarcinoma (PDAC)
Frontiers in Physiology
Physiology
PD-L1-specific Helper T-Cells Exhibit Effective Antitumor Responses: New Strategy of Cancer Immunotherapy Targeting PD-L1 in Head and Neck Squamous Cell Carcinoma
Journal of Translational Medicine
Biochemistry
Medicine
Genetics
Molecular Biology
Expression of PD‑1, PD‑L1 and PD‑L2 Is Associated With Differentiation Status and Histological Type of Endometrial Cancer
Oncology Letters
Cancer Research
Oncology
The Role of PD-1/PD-L1 Axis in Treg Development and Function: Implications for Cancer Immunotherapy
OncoTargets and Therapy
Oncology
Pharmacology
The JAK/STAT Pathway Is Involved in the Upregulation of PD-L1 Expression in Pancreatic Cancer Cell Lines
Oncology Reports
Medicine
Cancer Research
Oncology
